GEORGE TOWN, March 2 — The ProDetect® COVID-19 Antigen Rapid Test, manufactured in Malaysia by Medical Innovation Ventures Sdn Bhd (Mediven), has recently obtained a 100 per cent accuracy score in the well-regarded External Quality Assessment Programme (EQAP) conducted by the European Society for external quality assessment (EsFEQA).
Mediven, a Penang-based medical diagnostic company, develops, manufactures, and markets advanced high quality clinical diagnostic molecular and rapid tests.
In a statement today, Mediven operations director Dr Lim Li Sze said the COVID-19 rapid test serves as a valuable initial screening tool and as confirmed in the EQAP, the company’s ProDetect® test kit retained its quality and consistency in providing a high level of accuracy.
“As cases are rising by the day, it is crucial for early detection, isolation, and treatment of those infected and to prevent the further spread of COVID-19 infections,” Lim added.
Meanwhile, executive director Ariff Ismail said Mediven’s achievement in the EQAP assessment serves as a testament to the company’s dedication and mission to deliver cutting-edge diagnostics technology.
The ProDetect® Test-Kit provides test results within 20 minutes and is able to screen for all variants of concern, including Delta and Omicron.
Mediven® has two ranges of ProDetect® test kits for the detection of COVID-19, whereby the professional use either one of two types of samples; oral fluid and nasopharyngeal swab whereas self-test kits would use either saliva or nasal sample.
The company has also recently partnered with MyDocLab to launch a healthcare app to enable schools, corporates, and individuals manage their employee and self-health status effectively and allows easy professional antigen rapid test reporting for international border crossing from the comfort of one’s home.
It said the app could also generate official professionally certified report which is needed for Vaccinated Travel Lane (VTL) travelling.